{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-013726","form_type":"8-K","ticker":"BMY","cik":"0000014272","company_name":"BRISTOL MYERS SQUIBB CO","filed_at":"2024-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.157958+00:00","generated_at":"2026-06-04T14:55:54.148131+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Bristol-Myers Squibb completes $330/share acquisition of Karuna Therapeutics, adds schizophrenia drug KarXT","bullets":["Each Karuna share converted into $330 cash; deal closed March 18, 2024.","Lead asset KarXT (xanomeline-trospium) has PDUFA date Sept 26, 2024 for schizophrenia.","Transaction expected to be dilutive ~$0.30 to non-GAAP EPS in 2024 from financing costs.","One-time ~$12B Acquired IPR&D charge impacts Q1 2024 GAAP/non-GAAP EPS by ~$5.93.","BMS to update financial outlook when reporting Q1 2024 results on April 25."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-013726","json":"https://secwatch.observer/filing/0001140361-24-013726.json","markdown":"https://secwatch.observer/filing/0001140361-24-013726.md","text":"https://secwatch.observer/filing/0001140361-24-013726.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/14272/000114036124013726/0001140361-24-013726-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/14272/000114036124013726/ef20024275_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T14:55:54.148131+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}